Roche's non-voting equity securities and Roche bearer shares are listed on SIX Swiss Exchange. Roche’s American Depositary Receipt (ADR) is listed on OTCQX International Premier under the ticker RHHBY.
The Company has a share capital of CHF 106,691,000, divided into 106,691,000 fully paid bearer shares with a nominal value of 1 Swiss franc each. There are no limitations on the transfer of these shares and no shares with maximum voting rights (please refer to § 3ss. of the Articles of Incorporation of Roche Holding Ltd.).
In addition, 702,562,700 non-voting equity securities have been issued in bearer form. Roche’s non-voting equity securities and the rights pertaining thereto are described in §4ss. of the Articles of Incorporation of Roche Holding Ltd.
For more information, please read the
At 31 December 2022 the authorised and issued share capital of Roche Holding Ltd, which is the Group’s parent company, consisted of 106,691,000 shares with a nominal value of CHF 1.00 each (31 December 2021: 160,000,000 shares, there of 53,309,000 shares held by the Group as treasury shares that were cancelled in February 2022). The shares are bearer shares and the Group does not maintain a register of shareholders. At 10 February 2023, based on information supplied to the Group, a shareholder group with pooled voting rights owned 69,318,000 shares representing 64.97% of the issued shares (31December 2022: 72,018,000 shares representing 67.50% of the issued shares). These figures do not include any shares without pooled voting rights that are held outside this group by individual members of the group. The duration of the shareholder pooling agreement existing since 1948 was extended for an indefinite period in 2009. On 5 December 2019 the shareholder group announced that it would continue the pool with a modified shareholder composition. At 31 December 2022, based on information supplied to the Group, Ms Maja Oeri, formerly a member of the pool, held 8,091,900 shares independently of the pool, representing 7.58% of the issued shares (31 December 2021: 8,091,900 shares representing 5.057% of the issued shares and, excluding the treasury shares held by the Group that were cancelled in February 2022, 7.58% of the voting power).
Equity research on Roche is provided by the following institutions. We provide the names of institutions for your convenience only. We do not endorse or express any opinion on their reports and expressly disclaim any liability for any of their statements and for the use of such third party information. The list does not purport to be complete, correct or representative. The list may be updated from time to time, but no assurance is given that the list is current or accurate as of any point in time.
Institutions
Alliance Bernstein
Bank of America
Bank Vontobel AG
Barclays
Berenberg
Citi
Cowen & Co
Credit Suisse
Deutsche Bank
Exane BNP Paribas
HSBC
Intron Health
Jefferies
JPMorgan
Kepler Cheuvreux
Liberum
Mirabaud Securities
Morgan Stanley
Morningstar Inc
New Street Research
ODDO Securities
Redburn (Europe) Limited
Société Générale
Stifel
UBS
Wolfe Research
Zürcher Kantonalbank (ZKB)
The next Annual General Meeting of Roche Holding Ltd is expected to take place on 12 March 2024.
Timetable for payment of the 2022 dividend
Timetable for payment of the 2022 dividend
Declaration date is the date of approval of the proposed dividend at the Annual General Meeting
Ex-dividend date is the first date where trading takes place without dividend
Record date is the last date on which the security must be held in custody in order to be eligible to receive dividend.
Beginning in 2019, Roche Holding Ltd dividend to ADR holders will be paid in two stages. The first payment will be less 35% Swiss withholding tax, payable one week after Swiss pay date. Those eligible holders reclaiming Swiss withholding tax will receive a second payment once the reclaim process is completed.
This investor tool provides advanced analysis of total returns over time including dividend history and a calculator that can be used to determine the value and total return of your investment.
Data per share and non-voting equity security in CHF
Market capitalisation in millions of CHF
Key ratios (year-end)
a) Each non-voting equity security (Genussschein) confers the same rights as any of the shares to participate in the available earnings and any remaining proceeds from liquidation following repayment of the nominal value of the shares and the participation certificate capital (if any). Shares and non-voting equity securities are listed on the SIX Swiss Exchange. Roche Holding Ltd has no restrictions as to ownership of its shares or non-voting equity securities.
b) All stock price data reflect daily closing prices.
Yearly Dividend Payout
Number of shares and non-voting equity securities a)
Bond information
Last update: February 2023
Bond maturity profile
Information about Roche's current bonds and notes
This is not an offer of Securities for sale. The Bonds and Notes have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Bonds and Notes may not be offered or sold in the United States or to U.S. persons (as defined in Regulation S) except in transactions exempt from, or not subject to, the registration requirements of the Securities Act.
Roche Finance Europe B.V. (The Netherlands) guaranteed by Roche Holding Ltd (Switzerland)
EMTN Programme; listed in Luxembourg
EMTN Programme; listed in Luxembourg
EUR standalone, primary listing at SIX (Switzerland)
Roche Kapitalmarkt AG (Switzerland) guaranteed by Roche Holding Ltd (Switzerland)
Swiss issuer: 35% withholding tax on coupon payments Standalone Swiss documentation; listed at SIX (Switzerland)
Roche Holdings, Inc. (USA) guaranteed by Roche Holding Ltd (Switzerland)
144a / RegS US documentation; not listed
Genentech, Inc.
US documentation, not listed
Credit Rating
Last update: October, 2022